Narrow HCC CheckMate-459 Miss For Opdivo Points The Way For Combos, Roche Shows How
Executive Summary
Full data at ESMO show Opdivo managed to scrape a tolerability edge over standard-of-care sorafenib in liver cancer, but eyes were drawn to Roche’s early study of Tecentriq/Avastin as the way forward in this difficult-to-treat cancer.
You may also be interested in...
ASCO 2020: Roche Highlights TIGIT As Tecentriq Bags Another Approval
The Swiss major focused almost exclusively on the benefits of the combination of Tecentriq and its TIGIT inhibitor tiragolumab at ASCO but also celebrated the approval of a Tecentriq/Avastin combo for hepatocellular carcinoma.
Keeping Track Of Review Designations: BTDs For X4, F2G, And BMS; Another QIDP For Allergan
The latest news about products accepted into US FDA expedited review programs.
Roche Notches Big IO Win With Tecentriq/Avastin Combo In First-Line HCC
Following quickly on a Bristol trial failure with Opdivo in first-line HCC, Roche’s PD-L1 inhibitor looks poised to be the first immunotherapy approved in the setting, with plans for US, EU and China filings.